Status:
COMPLETED
Escitalopram (Lexapro) for Depression MS or ALS
Lead Sponsor:
University of South Carolina
Conditions:
Major Depression
Multiple Sclerosis
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.
Detailed Description
This eight-week study aims to assess the effectiveness and tolerability of escitalopram in improving symptoms of Major Depression in patients with Amyotrophic Lateral Sclerosis (ALS) or Multiple Scler...
Eligibility Criteria
Inclusion
- Patients between 18 and 70 years of age with documented ALS or MS,
- DSM-IV episode of non-psychotic Major Depression,
- ≥14 score on the 17-item HAM-D,
- Ability to give informed consent.
Exclusion
- History of psychotic disorders,
- Psychotic depression,
- Bipolar depression,
- Suicide risk,
- History of substance abuse in the previous 6 months,
- History of unstable medical disorders,
- Pregnancy or planning for pregnancy,
- Severity of ALS or MS that limits participating in the study protocol.
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2010
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00965497
Start Date
July 1 2009
End Date
March 1 2010
Last Update
May 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of South Carolina School of Medicine
Columbia, South Carolina, United States, 20203